To include your compound in the COVID-19 Resource Center, submit it here.

Depomed falls on 2Q11 results, higher expenses

Depomed Inc. (NASDAQ:DEPO) fell $1.18 (15%) to $6.52 on Tuesday after reporting 2Q11 results that missed the Street's expectations as well

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE